Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Asymptomatic visual loss in multiple sclerosis.

J Lycke1, P O Tollesson, L Frisén

  • 1Institute of Clinical Neuroscience, Department of Neurology, Göteborg University, Sahlgren's University Hospital, Sweden. jan.lycke@neuro.gu.se

Journal of Neurology
|May 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing-Remitting MS.

Annals of clinical and translational neurology·2026
Same author

The value of CSF diagnostic and prognostic biomarkers in NMOSD and MOGAD in real-life use.

Multiple sclerosis and related disorders·2025
Same author

Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2024
Same author

Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.

Multiple sclerosis and related disorders·2022
Same author

NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS.

Multiple sclerosis and related disorders·2020
Same author

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.

European journal of neurology·2019

Asymptomatic visual loss is common in multiple sclerosis (MS) and impacts visual pathways early. This silent disease activity, detected by computerised resolution perimetry, shows significant retino-cortical channel loss even without prior optic neuritis.

Area of Science:

  • Neuroscience
  • Ophthalmology
  • Neurology

Background:

  • Visual disturbances are frequent in multiple sclerosis (MS), often linked to optic nerve inflammation.
  • Subtle, asymptomatic visual loss can occur in MS patients even without a history of optic neuritis.

Purpose of the Study:

  • To investigate silent disease activity and asymptomatic visual loss in MS using computerised resolution perimetry.
  • To assess the extent and evolution of visual pathway damage in MS patients, with and without a history of optic neuritis.

Main Methods:

  • Retrospective analysis of 16 MS patients without optic neuritis history, monitored for 5.5-9 years using computerised resolution perimetry.
  • Prospective testing of 7 MS patients with initial clinical exacerbations but no prior visual symptoms.

Related Experiment Videos

  • Comparison of results with 14 healthy controls and 25 MS patients with a history of optic neuritis.

    • Main Results:

    • MS patients without optic neuritis history showed a 20% loss of functional retino-cortical neural channels compared to controls.
    • MS patients with prior optic neuritis experienced a 30% loss of these channels.
    • Asymptomatic visual loss was present at disease onset and showed minimal progression over several years.

    Conclusions:

    • Asymptomatic visual loss is a common feature of MS, significantly affecting visual pathways.
    • This silent visual damage is present early in the disease course and progresses slowly.
    • Computerised resolution perimetry is a valuable tool for detecting subclinical visual impairment in MS.